Neurocrine Biosciences, Inc. (NB3.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 10:16AM CEST
| Previous close | 134.80 |
| Open | 129.65 |
| Bid | 130.50 x 50000 |
| Ask | 130.80 x 50000 |
| Day's range | 129.65 - 130.95 |
| 52-week range | 83.18 - 135.35 |
| Volume | |
| Avg. volume | 15 |
| Market cap | 13.178B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 38.07 |
| EPS (TTM) | 3.44 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 122.19 |
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.
Simply Wall St.Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations
Neurocrine Biosciences ( NASDAQ:NBIX ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from...
- GuruFocus.com
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
INGREZZA drives strong sales while new drug approvals and a solid cash position underscore a promising future.
© 2024 Yahoo. All rights reserved.